Galectin Therap Trials - LARVOL Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Davanat (galactomannan) / Galectin Therap

2010-018638-29: Anti-tumoral vaccination of melanoma patients with peptides associated with GM-CT-01, a vegetal derived sugar that binds to and blocks galectin, a protein produced by tumor cells that inhibits immune cells.

Ongoing

1/2

Europe

MAGE-3.A1 peptide, NA17.A2 peptide, GM-CT-01, MAGE-3.A1, NA17.A2, Powder for suspension for injection, Solution for infusion

Centre du Cancer des Cliniques Universitaires Saint-Luc, Centre du Cancer, Cliniques Universitaires Saint-Luc, Ludwig Institute for Cancer Research, Galectin Therapeutics

Metastatic melanoma, Metastatic melanoma, Diseases [C] - Cancer [C04]

belapectin (GR-MD-02) / Galectin Therap

2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis.

Not yet recruiting

2/3

395

Europe, RoW

Belapectin, GR-MD-02, Solution for infusion

Galectin Therapeutics Inc., Galectin Therapeutics Inc

Esophageal Varices in NASH Cirrhosis, Varices (enlarged veins) in oesophagus (muscular tube connecting the throat with the stomach) in patients with liver cirrhosis (scarring) due to non-alcoholic fatty liver disease with inflammation., Diseases [C] - Nutritional and Metabolic Diseases [C18]

NAVIGATE, NCT04365868: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting

357

Europe, Canada, US, RoW

belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo

Galectin Therapeutics Inc.

Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis

12/24

NCT02575404: GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

	Additional preliminary data from cohort 3 in combination with Keytruda for melanoma and HNC
	Sep 2018 - Sep 2018: Additional preliminary data from cohort 3 in combination with Keytruda for melanoma and HNC
	From study in combination with Keytruda for melanoma, NSCLC and HNSCC [screenshot]
	Feb 2018 - Feb 2018: From study in combination with Keytruda for melanoma, NSCLC and HNSCC [screenshot]
	From trial in combination with GR-MD-02 for melanoma, HNSCC and NSCLC [screenshot]
	Nov 2017 - Nov 2017: From trial in combination with GR-MD-02 for melanoma, HNSCC and NSCLC [screenshot]
More

Completed

GR-MD-02, Galactoarabino-rhamnogalactouronate, Pembrolizumab, Keytruda

Providence Health & Services, Galectin Therapeutics Inc.

Melanoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck

01/21

10/22

galectin 3 inhibitors / Galectin Therap

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites